- Home
- HBANZ vs GEHC Comparison
HBANZ vs GEHC Comparison
Compare HBANZ & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HBANZ
Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/1000th Interest in a Share of 5.50% Series L Non-Cumulative Perpetual Preferred Stock
Current Price
Company Overview
Basic Information| Metric | HBANZ | GEHC |
|---|---|---|
| Founded | N/A | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Computer Software: Prepackaged Software |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 38.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HBANZ | GEHC |
|---|---|---|
| Price | $21.55 | $78.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $91.17 |
| AVG Volume (30 Days) | N/A | ★ 4.0M |
| Earning Date | N/A | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.18% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 4.55 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | N/A | $5.90 |
| Revenue Next Year | N/A | $4.52 |
| P/E Ratio | ★ N/A | $17.41 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | N/A | $57.65 |
| 52 Week High | N/A | $94.80 |
Technical Indicators
Market Signals| Indicator | HBANZ | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.44 |
| Support Level | N/A | $78.59 |
| Resistance Level | N/A | $80.59 |
| Average True Range (ATR) | 0.00 | 2.22 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 0.00 | 15.88 |
Price Performance
Historical ComparisonAbout GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).